Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
05 févr. 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
08 janv. 2024 06h30 HE
|
Beam Therapeutics
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
14 déc. 2023 06h30 HE
|
Beam Therapeutics
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
08 nov. 2023 06h30 HE
|
Beam Therapeutics
Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’...
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
08 nov. 2023 06h30 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
31 oct. 2023 06h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
25 oct. 2023 06h30 HE
|
Beam Therapeutics
Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. Investigational New Drug (IND) Application for...
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
19 oct. 2023 08h45 HE
|
Beam Therapeutics
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to...
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
07 sept. 2023 10h00 HE
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new...